TLC-2716

Phase 2Small molecule

OOrsoBio, Inc

TLC-2716 is one of 15 small molecule programs targeting Hypertriglyceridemia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HypertriglyceridemiaRecruiting

HypertriglyceridemiaPhase 2

Recruiting

Competition

Competitive Landscape

17 competitors in Hypertriglyceridemia

#DrugCompanyPhaseTrials

Crestor

Cipro

Lopid

Selzentry

Topamax

Zocor

Tryngolza (autoinjector)

Ionis Pharmaceuticals

Phase 3

3 8

Redemplo

Arrowhead Pharmaceuticals

Phase 3

3 9

Avandia

Jazz Pharmaceuticals

Preclinical

1 10

Repatha

Amgen

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hypertriglyceridemia1 trial

Phase 2a Study of Safety, Tolerability, and Efficacy of TLC-2716 in Subjects With Hypertriglyceridemia and NAFLD

Recruiting·OOrsoBio, Inc·Phase 2·NCT06564584·30 enrolled

ART1 trial

A Study to Evaluate Single and Multiple Doses of TLC-2716 in Healthy Participants

Completed·OOrsoBio, Inc·Phase 1·NCT05483998·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for TLC-2716. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TLC-2716 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TLC-2716. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — OrsoBio, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: OOrsoBio, Inc

TLC-2716

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hypertriglyceridemia1 trial

ART1 trial

References

Drug Info

Quick Facts

Related News